DS
RGLS

David Shaw’s Regulus Therapeutics RGLS Stock Holding History

David Shaw’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-228
Closed -$28K – 3742
2017
Q4 		$28K Sell
228
-20
-8% -$2.53K ﹤0.01% 3541
2017
Q3 		$37K Buy
+248
New +$31.2K ﹤0.01% 3413
2017
Q1 		– Sell
-516
Closed -$139K – 3547
2016
Q4 		$139K Buy
516
+42
+9% +$13.7K ﹤0.01% 3322
2016
Q3 		$187K Buy
+474
New +$195K ﹤0.01% 3214
2016
Q2 		– Sell
-572
Closed -$476K – 3496
2016
Q1 		$476K Sell
572
-322
-36% -$256K ﹤0.01% 2810
2015
Q4 		$935K Buy
894
+462
+107% +$463K ﹤0.01% 2682
2015
Q3 		$339K Buy
+432
New +$443K ﹤0.01% 3289
2015
Q2 		– Sell
-104
Closed -$212K – 3848
2015
Q1 		$212K Buy
+104
New +$226K ﹤0.01% 3433
2013
Q4 		– Sell
-212
Closed -$240K – 4659
2013
Q3 		$240K Buy
+212
New +$250K ﹤0.01% 4010

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SDIC
South Dakota Investment Council Sioux Falls, South Dakota $5.84B AUM 30.42% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AC
Ascend Capital Orinda, California $1.99B AUM 10.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

David Shaw's RGLS Position: Q1 2018 in Review

David Shaw sold out of Regulus Therapeutics (RGLS) in Q1 2018, closing a stake of 228 shares — an estimated $28K sold.

David Shaw first reported a position in RGLS in Q3 2013 and held it in 9 quarters. The position peaked at $935K in Q4 2015. 50 funds tracked by Wall St. Rank hold RGLS as of Q1 2018.

  • David Shaw reported no remaining Regulus Therapeutics position as of Q1 2018 after selling out during the quarter.
  • David Shaw sold 228 Regulus Therapeutics shares in Q1 2018, an estimated $28K.
  • David Shaw first reported a position in Regulus Therapeutics in Q3 2013 and held it in 9 quarters.
  • David Shaw's Regulus Therapeutics position peaked at $935K in Q4 2015.
  • 50 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q1 2018.

Based on D.E. Shaw & Co's 13F filing for Q1 2018, filed 15 May 2018.